Dimension Therapeutics, which is developing novel, liver-directed gene therapies for rare genetic disorders, announced terms for its IPO on Tuesday.
The Cambridge, MA-based company plans to raise $83 million by offering 5.5 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Dimension Therapeutics would command a fully diluted market value of $410 million.
Dimension Therapeutics, which was founded in 2013 and booked $6 million in collaboration revenue for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol DMTX. Goldman Sachs and Citi are the joint bookrunners on the deal. It is expected to price during the week of October 19, 2015.
